Summary
Although diseases afflicting less than 1 person in 2000 are defined as rare diseases, the approx. 6000 different rare diseases together cause, nonetheless, a major burden on human wellbeing and the health systems. Over 90% of all rare diseases are currently without approved treatment and approx. 80% of them are genetic in origin. However, the research on rare diseases and the development of new diagnostic and therapeutic approaches is often hampered by limited resources, including patient material and biological models. The frequency of rare diseases increases in populations with a high frequency of consanguineous marriages. Within ERA, Turkey has the highest rate of consanguineous marriages and, consequently, rare diseases are about twice as prevalent in Turkey than in other ERA countries. The aim of this RareBoost project is to attract an internationally recognized rare disease expert (ERA Chair holder) to the Izmir Biomedicine and Genome Center (IBG), where s/he will lead and direct the new Unit for Rare Diseases and guide its development towards an internationally recognized research facility for rare diseases. IBG is perfectly suited for this development, as it is (i) the largest and best-equipped public biomedical research institute in Turkey, (ii) the only nationally recognized Centre of Excellence in the biomedical sciences, and (iii) already made significant steps towards research excellence. This RareBoost project will greatly facilitate IBG’s aim to become a leading basic and translational research centre for rare diseases. Furthermore, by becoming an internationally recognized hub for rare disease research, IBG will act as a guide for the Turkish R&D sector, will facilitate ERA homogeneity and will support the well-being of rare disease patients. Therefore, RareBoost will greatly boost IBG’s ability to increase ERA-wide cohesion, to support innovation for diagnostics and therapies of certain rare diseases, and to reduce patient suffering.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/952346 |
| Start date: | 01-10-2020 |
| End date: | 30-09-2026 |
| Total budget - Public funding: | 2 499 125,00 Euro - 2 499 125,00 Euro |
Cordis data
Original description
Although diseases afflicting less than 1 person in 2000 are defined as rare diseases, the approx. 6000 different rare diseases together cause, nonetheless, a major burden on human wellbeing and the health systems. Over 90% of all rare diseases are currently without approved treatment and approx. 80% of them are genetic in origin. However, the research on rare diseases and the development of new diagnostic and therapeutic approaches is often hampered by limited resources, including patient material and biological models. The frequency of rare diseases increases in populations with a high frequency of consanguineous marriages. Within ERA, Turkey has the highest rate of consanguineous marriages and, consequently, rare diseases are about twice as prevalent in Turkey than in other ERA countries. The aim of this RareBoost project is to attract an internationally recognized rare disease expert (ERA Chair holder) to the Izmir Biomedicine and Genome Center (IBG), where s/he will lead and direct the new Unit for Rare Diseases and guide its development towards an internationally recognized research facility for rare diseases. IBG is perfectly suited for this development, as it is (i) the largest and best-equipped public biomedical research institute in Turkey, (ii) the only nationally recognized Centre of Excellence in the biomedical sciences, and (iii) already made significant steps towards research excellence. This RareBoost project will greatly facilitate IBG’s aim to become a leading basic and translational research centre for rare diseases. Furthermore, by becoming an internationally recognized hub for rare disease research, IBG will act as a guide for the Turkish R&D sector, will facilitate ERA homogeneity and will support the well-being of rare disease patients. Therefore, RareBoost will greatly boost IBG’s ability to increase ERA-wide cohesion, to support innovation for diagnostics and therapies of certain rare diseases, and to reduce patient suffering.Status
SIGNEDCall topic
WIDESPREAD-06-2020Update Date
17-05-2024
Images
No images available.
Geographical location(s)
